Skip to main content
. Author manuscript; available in PMC: 2016 Jul 6.
Published in final edited form as: Nature. 2016 Jan 6;529(7586):413–417. doi: 10.1038/nature16508

Extended Data Figure 10.

Extended Data Figure 10

Overcoming BBI-resistance. a-c, Synergy studies of JQ1 with ABT737 (BCL-xl and BCL-2 inhibitor) (a), CX-4945 (CK2 inhibitor) (b) and Perphenazine (PP2A activator) (c). Points represent paired values of drug concentrations assessed for synergism. The diagonal line signifies drug additivity. Points above the line represent antagonistic drug combinations, and those below the line represent synergistic drug combinations.